Septerna Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Septerna Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
South SAN Francisco
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
SEPN
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001984086
EIN
84-3891440

Board of directors

Follow this board

Chief executives

Jeffrey Finer · CEO and President
Dates unknown

Director election results

Annual meeting of June 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

9 of this board's directors also sit on 33 other boards.

Network of Septerna Inc.'s board connections Bicara Therapeutics Inc. Bicara Therapeutics In... Janux Therapeutics Inc. Janux Therapeutics Inc... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Parabilis Medicines Inc. Parabilis Medicines In... Tyra Biosciences Inc. Tyra Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Mineralys Therapeutics Inc. Mineralys Therapeutics... Abraham Bassan Abraham Bassan Jake Simson Jake Simson Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Septerna Inc.
Shared director Other board Same sector +17 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$76,055,042
27 sales by 5 insiders
Date Insider Transaction Shares Price Value
Sep 1, 2026 Long Daniel D. Officer (SVP, Drug Discovery) Option exercise +3,333 $2.76 $9,199
Sep 1, 2026 Long Daniel D. Officer (SVP, Drug Discovery) Open-market sale −3,333 $37.83 $126,078
Aug 12, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −746,500 $42.50 $31,726,250
Aug 12, 2026 Third Rock Ventures V, L.P. 10% owner Open-market sale +147,059 $50.27 $7,392,656
Aug 12, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −746,500 $42.50 $31,726,250
Aug 12, 2026 Third Rock Ventures V, L.P. 10% owner Open-market sale +141 $51.08 $7,202
Aug 11, 2026 Bhatt Elizabeth Officer (President and COO) Option exercise +18,681 $6.81 $127,218
Aug 11, 2026 Bhatt Elizabeth Officer (President and COO) Option exercise +6,319 $2.76 $17,440
Aug 11, 2026 Bhatt Elizabeth Officer (President and COO) Open-market sale −25,000 $44.00 $1,100,000
Aug 3, 2026 Long Daniel D. Officer (SVP, Drug Discovery) Option exercise +1,816 $2.76 $5,012
Aug 3, 2026 Long Daniel D. Officer (SVP, Drug Discovery) Option exercise +1,518 $2.76 $4,190
Aug 3, 2026 Long Daniel D. Officer (SVP, Drug Discovery) Open-market sale −1,000 $33.98 $33,976
Aug 3, 2026 Long Daniel D. Officer (SVP, Drug Discovery) Open-market sale −2,334 $34.68 $80,944
Jul 15, 2026 Bhatt Elizabeth Officer (President and COO) Option exercise +4,000 $6.81 $27,240
Jul 15, 2026 Bhatt Elizabeth Officer (President and COO) Open-market sale −4,000 $33.99 $135,974

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.